nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—thyroid cancer—kidney cancer	0.153	0.509	CtDrD
Sorafenib—liver cancer—kidney cancer	0.147	0.491	CtDrD
Sorafenib—RAF1—kidney cancer	0.057	0.256	CbGaD
Sorafenib—FLT1—kidney cancer	0.0536	0.241	CbGaD
Sorafenib—BRAF—kidney cancer	0.0395	0.177	CbGaD
Sorafenib—KDR—kidney cancer	0.0336	0.151	CbGaD
Sorafenib—KIT—kidney cancer	0.0317	0.142	CbGaD
Sorafenib—AURKC—Pazopanib—kidney cancer	0.0141	0.0437	CbGbCtD
Sorafenib—FLT1—Pazopanib—kidney cancer	0.0141	0.0437	CbGbCtD
Sorafenib—FGFR1—Pazopanib—kidney cancer	0.0118	0.0365	CbGbCtD
Sorafenib—FLT4—Pazopanib—kidney cancer	0.0118	0.0365	CbGbCtD
Sorafenib—HIPK3—Sunitinib—kidney cancer	0.0115	0.0358	CbGbCtD
Sorafenib—KDR—Pazopanib—kidney cancer	0.0102	0.0316	CbGbCtD
Sorafenib—MKNK1—Erlotinib—kidney cancer	0.0101	0.0312	CbGbCtD
Sorafenib—AURKC—Erlotinib—kidney cancer	0.0101	0.0312	CbGbCtD
Sorafenib—EPHB6—Pazopanib—kidney cancer	0.009	0.0279	CbGbCtD
Sorafenib—KIT—Pazopanib—kidney cancer	0.00809	0.0251	CbGbCtD
Sorafenib—STK10—Pazopanib—kidney cancer	0.00809	0.0251	CbGbCtD
Sorafenib—PDGFRA—Pazopanib—kidney cancer	0.00809	0.0251	CbGbCtD
Sorafenib—CSF1R—Pazopanib—kidney cancer	0.00809	0.0251	CbGbCtD
Sorafenib—RALBP1—Vincristine—kidney cancer	0.00793	0.0246	CbGbCtD
Sorafenib—PDGFRB—Pazopanib—kidney cancer	0.00736	0.0228	CbGbCtD
Sorafenib—MAP2K5—Pazopanib—kidney cancer	0.00736	0.0228	CbGbCtD
Sorafenib—ABCB1—kidney cancer	0.0073	0.0328	CbGaD
Sorafenib—FLT3—Erlotinib—kidney cancer	0.00727	0.0225	CbGbCtD
Sorafenib—MAP3K19—Pazopanib—kidney cancer	0.00677	0.021	CbGbCtD
Sorafenib—MAP3K7—Sunitinib—kidney cancer	0.00662	0.0205	CbGbCtD
Sorafenib—AURKC—Sunitinib—kidney cancer	0.00662	0.0205	CbGbCtD
Sorafenib—FLT1—Sunitinib—kidney cancer	0.00662	0.0205	CbGbCtD
Sorafenib—HIPK4—Erlotinib—kidney cancer	0.00642	0.0199	CbGbCtD
Sorafenib—EPHA6—Erlotinib—kidney cancer	0.00642	0.0199	CbGbCtD
Sorafenib—STK10—Erlotinib—kidney cancer	0.00577	0.0179	CbGbCtD
Sorafenib—FLT4—Sunitinib—kidney cancer	0.00554	0.0172	CbGbCtD
Sorafenib—FGFR1—Sunitinib—kidney cancer	0.00554	0.0172	CbGbCtD
Sorafenib—MAP2K5—Erlotinib—kidney cancer	0.00525	0.0163	CbGbCtD
Sorafenib—RALBP1—Doxorubicin—kidney cancer	0.00496	0.0154	CbGbCtD
Sorafenib—MAP3K19—Erlotinib—kidney cancer	0.00483	0.015	CbGbCtD
Sorafenib—FLT3—Sunitinib—kidney cancer	0.00479	0.0148	CbGbCtD
Sorafenib—KDR—Sunitinib—kidney cancer	0.00479	0.0148	CbGbCtD
Sorafenib—RET—Sunitinib—kidney cancer	0.00479	0.0148	CbGbCtD
Sorafenib—HIPK4—Sunitinib—kidney cancer	0.00423	0.0131	CbGbCtD
Sorafenib—EPHB6—Sunitinib—kidney cancer	0.00423	0.0131	CbGbCtD
Sorafenib—STK10—renal vein—kidney cancer	0.00393	0.138	CbGeAlD
Sorafenib—STK10—Sunitinib—kidney cancer	0.0038	0.0118	CbGbCtD
Sorafenib—PDGFRA—Sunitinib—kidney cancer	0.0038	0.0118	CbGbCtD
Sorafenib—CSF1R—Sunitinib—kidney cancer	0.0038	0.0118	CbGbCtD
Sorafenib—KIT—Sunitinib—kidney cancer	0.0038	0.0118	CbGbCtD
Sorafenib—MAP2K5—Sunitinib—kidney cancer	0.00346	0.0107	CbGbCtD
Sorafenib—PDGFRB—Sunitinib—kidney cancer	0.00346	0.0107	CbGbCtD
Sorafenib—MAP3K19—Sunitinib—kidney cancer	0.00318	0.00987	CbGbCtD
Sorafenib—STK10—renal artery—kidney cancer	0.00264	0.0927	CbGeAlD
Sorafenib—UGT1A1—Pazopanib—kidney cancer	0.00243	0.00753	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Temsirolimus—kidney cancer	0.00188	0.00583	CbGbCtD
Sorafenib—CYP3A7—Temsirolimus—kidney cancer	0.00188	0.00583	CbGbCtD
Sorafenib—UGT1A1—Erlotinib—kidney cancer	0.00173	0.00538	CbGbCtD
Sorafenib—CYP3A5—Temsirolimus—kidney cancer	0.00141	0.00437	CbGbCtD
Sorafenib—ABCG2—Pazopanib—kidney cancer	0.00134	0.00414	CbGbCtD
Sorafenib—ABCG2—Dactinomycin—kidney cancer	0.00122	0.00379	CbGbCtD
Sorafenib—ABCC4—Sunitinib—kidney cancer	0.00117	0.00362	CbGbCtD
Sorafenib—ABCC2—Paclitaxel—kidney cancer	0.000965	0.00299	CbGbCtD
Sorafenib—ABCG2—Erlotinib—kidney cancer	0.000953	0.00296	CbGbCtD
Sorafenib—ABCB1—Temsirolimus—kidney cancer	0.000917	0.00284	CbGbCtD
Sorafenib—ABCG2—Paclitaxel—kidney cancer	0.000873	0.00271	CbGbCtD
Sorafenib—CYP2D6—Temsirolimus—kidney cancer	0.000864	0.00268	CbGbCtD
Sorafenib—ABCC2—Vinblastine—kidney cancer	0.000847	0.00263	CbGbCtD
Sorafenib—ABCC2—Vincristine—kidney cancer	0.000832	0.00258	CbGbCtD
Sorafenib—CYP3A4—Everolimus—kidney cancer	0.000813	0.00252	CbGbCtD
Sorafenib—ABCG2—Vincristine—kidney cancer	0.000752	0.00233	CbGbCtD
Sorafenib—CYP2C8—Pazopanib—kidney cancer	0.000712	0.00221	CbGbCtD
Sorafenib—CDKL3—gonad—kidney cancer	0.000703	0.0247	CbGeAlD
Sorafenib—UGT1A1—urine—kidney cancer	0.000699	0.0246	CbGeAlD
Sorafenib—ABCC2—Sunitinib—kidney cancer	0.000695	0.00215	CbGbCtD
Sorafenib—CYP3A7—Paclitaxel—kidney cancer	0.000644	0.002	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Paclitaxel—kidney cancer	0.000644	0.002	CbGbCtD
Sorafenib—CDKL2—gonad—kidney cancer	0.000643	0.0226	CbGeAlD
Sorafenib—ABCG2—Sunitinib—kidney cancer	0.000628	0.00195	CbGbCtD
Sorafenib—MAPK15—gonad—kidney cancer	0.000579	0.0203	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—Vincristine—kidney cancer	0.000556	0.00172	CbGbCtD
Sorafenib—CYP3A7—Vincristine—kidney cancer	0.000556	0.00172	CbGbCtD
Sorafenib—CYP1A2—Pazopanib—kidney cancer	0.000551	0.00171	CbGbCtD
Sorafenib—CYP3A4—Temsirolimus—kidney cancer	0.000549	0.0017	CbGbCtD
Sorafenib—CYP3A5—Erlotinib—kidney cancer	0.000528	0.00164	CbGbCtD
Sorafenib—ABCC2—Doxorubicin—kidney cancer	0.00052	0.00161	CbGbCtD
Sorafenib—CYP2C9—Capecitabine—kidney cancer	0.000518	0.00161	CbGbCtD
Sorafenib—Regorafenib—RAF1—kidney cancer	0.000516	0.249	CrCbGaD
Sorafenib—CYP2C8—Erlotinib—kidney cancer	0.000508	0.00158	CbGbCtD
Sorafenib—Regorafenib—FLT1—kidney cancer	0.000485	0.235	CrCbGaD
Sorafenib—CYP3A5—Paclitaxel—kidney cancer	0.000483	0.0015	CbGbCtD
Sorafenib—ABCB1—Pazopanib—kidney cancer	0.000482	0.00149	CbGbCtD
Sorafenib—ABCG2—Doxorubicin—kidney cancer	0.00047	0.00146	CbGbCtD
Sorafenib—CYP2C8—Paclitaxel—kidney cancer	0.000465	0.00144	CbGbCtD
Sorafenib—CYP3A7—Sunitinib—kidney cancer	0.000464	0.00144	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Sunitinib—kidney cancer	0.000464	0.00144	CbGbCtD
Sorafenib—CYP2D6—Pazopanib—kidney cancer	0.000454	0.00141	CbGbCtD
Sorafenib—ABCB1—Dactinomycin—kidney cancer	0.000441	0.00137	CbGbCtD
Sorafenib—CYP3A5—Vincristine—kidney cancer	0.000417	0.00129	CbGbCtD
Sorafenib—CYP1A2—Erlotinib—kidney cancer	0.000393	0.00122	CbGbCtD
Sorafenib—HIPK4—gonad—kidney cancer	0.00039	0.0137	CbGeAlD
Sorafenib—CYP2C19—urine—kidney cancer	0.000379	0.0133	CbGeAlD
Sorafenib—CDK7—renal system—kidney cancer	0.000377	0.0132	CbGeAlD
Sorafenib—Regorafenib—BRAF—kidney cancer	0.000358	0.173	CrCbGaD
Sorafenib—HIPK3—nephron tubule—kidney cancer	0.00035	0.0123	CbGeAlD
Sorafenib—ABCB1—Gemcitabine—kidney cancer	0.000348	0.00108	CbGbCtD
Sorafenib—CYP3A5—Sunitinib—kidney cancer	0.000348	0.00108	CbGbCtD
Sorafenib—ABCB1—Erlotinib—kidney cancer	0.000344	0.00107	CbGbCtD
Sorafenib—AURKC—gonad—kidney cancer	0.000333	0.0117	CbGeAlD
Sorafenib—CYP2B6—Doxorubicin—kidney cancer	0.000331	0.00103	CbGbCtD
Sorafenib—CYP2C9—Paclitaxel—kidney cancer	0.000324	0.00101	CbGbCtD
Sorafenib—CYP2D6—Erlotinib—kidney cancer	0.000324	0.001	CbGbCtD
Sorafenib—HIPK3—renal system—kidney cancer	0.000319	0.0112	CbGeAlD
Sorafenib—ABCB1—Paclitaxel—kidney cancer	0.000315	0.000976	CbGbCtD
Sorafenib—CYP1A2—urine—kidney cancer	0.000309	0.0109	CbGeAlD
Sorafenib—HIPK3—kidney—kidney cancer	0.000308	0.0108	CbGeAlD
Sorafenib—EPHA6—gonad—kidney cancer	0.000308	0.0108	CbGeAlD
Sorafenib—Regorafenib—KDR—kidney cancer	0.000304	0.147	CrCbGaD
Sorafenib—EPHX2—nephron tubule—kidney cancer	0.0003	0.0105	CbGeAlD
Sorafenib—CYP2C9—urine—kidney cancer	0.000294	0.0103	CbGeAlD
Sorafenib—CYP3A4—Pazopanib—kidney cancer	0.000289	0.000895	CbGbCtD
Sorafenib—Regorafenib—KIT—kidney cancer	0.000287	0.139	CrCbGaD
Sorafenib—HIPK3—gonad—kidney cancer	0.000286	0.01	CbGeAlD
Sorafenib—HIPK3—cardiac atrium—kidney cancer	0.000285	0.01	CbGeAlD
Sorafenib—ABCB1—Vinblastine—kidney cancer	0.000276	0.000856	CbGbCtD
Sorafenib—ABCB1—Vincristine—kidney cancer	0.000271	0.000842	CbGbCtD
Sorafenib—TIE1—cardiac atrium—kidney cancer	0.000267	0.00937	CbGeAlD
Sorafenib—CYP2D6—Vinblastine—kidney cancer	0.00026	0.000807	CbGbCtD
Sorafenib—EPHX2—cortex of kidney—kidney cancer	0.000257	0.00903	CbGeAlD
Sorafenib—UGT1A9—renal system—kidney cancer	0.00025	0.00877	CbGeAlD
Sorafenib—MKNK2—nephron tubule—kidney cancer	0.000245	0.00861	CbGeAlD
Sorafenib—FLT3—gonad—kidney cancer	0.000243	0.00854	CbGeAlD
Sorafenib—UGT1A9—kidney—kidney cancer	0.000241	0.00848	CbGeAlD
Sorafenib—FLT4—cortex of kidney—kidney cancer	0.000232	0.00814	CbGeAlD
Sorafenib—FGFR1—cortex of kidney—kidney cancer	0.000229	0.00803	CbGeAlD
Sorafenib—ABCB1—Sunitinib—kidney cancer	0.000226	0.000702	CbGbCtD
Sorafenib—CYP3A4—urine—kidney cancer	0.000224	0.00787	CbGeAlD
Sorafenib—MKNK2—renal system—kidney cancer	0.000223	0.00783	CbGeAlD
Sorafenib—CDK7—Idarubicin—Doxorubicin—kidney cancer	0.000223	0.333	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Doxorubicin—kidney cancer	0.000223	0.333	CbGdCrCtD
Sorafenib—CDK7—Epirubicin—Doxorubicin—kidney cancer	0.000223	0.333	CbGdCrCtD
Sorafenib—RALBP1—nephron tubule—kidney cancer	0.000221	0.00778	CbGeAlD
Sorafenib—CYP2D6—urine—kidney cancer	0.00022	0.00775	CbGeAlD
Sorafenib—FGFR1—cardiac atrium—kidney cancer	0.000217	0.00764	CbGeAlD
Sorafenib—RET—renal system—kidney cancer	0.000217	0.00763	CbGeAlD
Sorafenib—MAP3K7—cortex of kidney—kidney cancer	0.000216	0.0076	CbGeAlD
Sorafenib—FLT1—nephron tubule—kidney cancer	0.00021	0.0074	CbGeAlD
Sorafenib—RET—kidney—kidney cancer	0.00021	0.00738	CbGeAlD
Sorafenib—MKNK2—cortex of kidney—kidney cancer	0.00021	0.00737	CbGeAlD
Sorafenib—RAF1—nephron tubule—kidney cancer	0.000209	0.00735	CbGeAlD
Sorafenib—MKNK1—cortex of kidney—kidney cancer	0.000207	0.00728	CbGeAlD
Sorafenib—CYP3A4—Erlotinib—kidney cancer	0.000206	0.000639	CbGbCtD
Sorafenib—MAP3K7—cardiac atrium—kidney cancer	0.000206	0.00723	CbGeAlD
Sorafenib—RALBP1—renal system—kidney cancer	0.000201	0.00707	CbGeAlD
Sorafenib—MKNK2—gonad—kidney cancer	0.0002	0.00702	CbGeAlD
Sorafenib—MKNK2—cardiac atrium—kidney cancer	0.000199	0.00701	CbGeAlD
Sorafenib—MKNK1—gonad—kidney cancer	0.000197	0.00693	CbGeAlD
Sorafenib—MKNK1—cardiac atrium—kidney cancer	0.000197	0.00692	CbGeAlD
Sorafenib—RALBP1—kidney—kidney cancer	0.000194	0.00683	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—nephron tubule—kidney cancer	0.000194	0.00682	CbGeAlD
Sorafenib—FLT1—renal system—kidney cancer	0.000191	0.00672	CbGeAlD
Sorafenib—RAF1—renal system—kidney cancer	0.00019	0.00668	CbGeAlD
Sorafenib—RALBP1—cortex of kidney—kidney cancer	0.000189	0.00666	CbGeAlD
Sorafenib—CYP3A4—Paclitaxel—kidney cancer	0.000189	0.000585	CbGbCtD
Sorafenib—FLT1—kidney—kidney cancer	0.000185	0.0065	CbGeAlD
Sorafenib—RAF1—kidney—kidney cancer	0.000184	0.00646	CbGeAlD
Sorafenib—STK10—renal system—kidney cancer	0.000181	0.00636	CbGeAlD
Sorafenib—RALBP1—cardiac atrium—kidney cancer	0.00018	0.00633	CbGeAlD
Sorafenib—FLT1—cortex of kidney—kidney cancer	0.00018	0.00633	CbGeAlD
Sorafenib—PDGFRA—renal system—kidney cancer	0.000179	0.0063	CbGeAlD
Sorafenib—RAF1—cortex of kidney—kidney cancer	0.000179	0.00629	CbGeAlD
Sorafenib—EPHB6—cortex of kidney—kidney cancer	0.000178	0.00626	CbGeAlD
Sorafenib—KDR—nephron tubule—kidney cancer	0.000178	0.00625	CbGeAlD
Sorafenib—STK10—kidney—kidney cancer	0.000175	0.00615	CbGeAlD
Sorafenib—FLT1—gonad—kidney cancer	0.000172	0.00603	CbGeAlD
Sorafenib—FLT1—cardiac atrium—kidney cancer	0.000171	0.00602	CbGeAlD
Sorafenib—UGT1A1—renal system—kidney cancer	0.000171	0.00601	CbGeAlD
Sorafenib—RAF1—gonad—kidney cancer	0.000171	0.00599	CbGeAlD
Sorafenib—RAF1—cardiac atrium—kidney cancer	0.00017	0.00599	CbGeAlD
Sorafenib—ABCB1—Doxorubicin—kidney cancer	0.00017	0.000526	CbGbCtD
Sorafenib—EPHB6—cardiac atrium—kidney cancer	0.000169	0.00595	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—cortex of kidney—kidney cancer	0.000166	0.00584	CbGeAlD
Sorafenib—CYP3A4—Vinblastine—kidney cancer	0.000165	0.000513	CbGbCtD
Sorafenib—UGT1A1—kidney—kidney cancer	0.000165	0.00581	CbGeAlD
Sorafenib—CYP3A4—Vincristine—kidney cancer	0.000163	0.000504	CbGbCtD
Sorafenib—STK10—gonad—kidney cancer	0.000162	0.00571	CbGeAlD
Sorafenib—KDR—renal system—kidney cancer	0.000162	0.00568	CbGeAlD
Sorafenib—PDGFRA—gonad—kidney cancer	0.000161	0.00565	CbGeAlD
Sorafenib—CYP2D6—Doxorubicin—kidney cancer	0.00016	0.000496	CbGbCtD
Sorafenib—KIT—nephron tubule—kidney cancer	0.000158	0.00554	CbGeAlD
Sorafenib—KDR—kidney—kidney cancer	0.000156	0.0055	CbGeAlD
Sorafenib—KDR—cortex of kidney—kidney cancer	0.000152	0.00535	CbGeAlD
Sorafenib—MAP2K5—cortex of kidney—kidney cancer	0.000152	0.00535	CbGeAlD
Sorafenib—KDR—cardiac atrium—kidney cancer	0.000145	0.00509	CbGeAlD
Sorafenib—MAP2K5—cardiac atrium—kidney cancer	0.000145	0.00509	CbGeAlD
Sorafenib—KIT—renal system—kidney cancer	0.000143	0.00504	CbGeAlD
Sorafenib—CSF1R—gonad—kidney cancer	0.000142	0.00497	CbGeAlD
Sorafenib—CSF1R—cardiac atrium—kidney cancer	0.000141	0.00497	CbGeAlD
Sorafenib—PDGFRB—renal system—kidney cancer	0.00014	0.00492	CbGeAlD
Sorafenib—KIT—kidney—kidney cancer	0.000139	0.00487	CbGeAlD
Sorafenib—CYP3A4—Sunitinib—kidney cancer	0.000136	0.000421	CbGbCtD
Sorafenib—PDGFRB—kidney—kidney cancer	0.000135	0.00476	CbGeAlD
Sorafenib—KIT—cortex of kidney—kidney cancer	0.000135	0.00474	CbGeAlD
Sorafenib—PDGFRB—cortex of kidney—kidney cancer	0.000132	0.00463	CbGeAlD
Sorafenib—KIT—gonad—kidney cancer	0.000129	0.00452	CbGeAlD
Sorafenib—PDGFRB—gonad—kidney cancer	0.000126	0.00441	CbGeAlD
Sorafenib—PDGFRB—cardiac atrium—kidney cancer	0.000125	0.00441	CbGeAlD
Sorafenib—ABCC4—nephron tubule—kidney cancer	0.000123	0.00431	CbGeAlD
Sorafenib—ABCC2—nephron tubule—kidney cancer	0.000119	0.00417	CbGeAlD
Sorafenib—ABCC4—renal system—kidney cancer	0.000111	0.00392	CbGeAlD
Sorafenib—ABCC2—renal system—kidney cancer	0.000108	0.00379	CbGeAlD
Sorafenib—ABCC4—kidney—kidney cancer	0.000108	0.00379	CbGeAlD
Sorafenib—ABCC4—cortex of kidney—kidney cancer	0.000105	0.00369	CbGeAlD
Sorafenib—HTR2B—cortex of kidney—kidney cancer	0.000104	0.00367	CbGeAlD
Sorafenib—ABCC2—kidney—kidney cancer	0.000104	0.00367	CbGeAlD
Sorafenib—CYP3A4—Doxorubicin—kidney cancer	0.000102	0.000315	CbGbCtD
Sorafenib—ABCC2—cortex of kidney—kidney cancer	0.000102	0.00357	CbGeAlD
Sorafenib—ABCG2—nephron tubule—kidney cancer	8.65e-05	0.00304	CbGeAlD
Sorafenib—CYP2C8—renal system—kidney cancer	8.09e-05	0.00284	CbGeAlD
Sorafenib—CYP3A5—nephron tubule—kidney cancer	8.03e-05	0.00282	CbGeAlD
Sorafenib—CYP2B6—nephron tubule—kidney cancer	7.98e-05	0.00281	CbGeAlD
Sorafenib—CYP2C8—kidney—kidney cancer	7.82e-05	0.00275	CbGeAlD
Sorafenib—CYP1A2—renal system—kidney cancer	7.57e-05	0.00266	CbGeAlD
Sorafenib—CYP3A5—renal system—kidney cancer	7.3e-05	0.00257	CbGeAlD
Sorafenib—CYP2B6—renal system—kidney cancer	7.26e-05	0.00255	CbGeAlD
Sorafenib—CYP3A5—kidney—kidney cancer	7.06e-05	0.00248	CbGeAlD
Sorafenib—CYP2B6—kidney—kidney cancer	7.02e-05	0.00247	CbGeAlD
Sorafenib—CYP3A5—cortex of kidney—kidney cancer	6.88e-05	0.00242	CbGeAlD
Sorafenib—Regorafenib—ABCB1—kidney cancer	6.61e-05	0.032	CrCbGaD
Sorafenib—CYP2B6—gonad—kidney cancer	6.51e-05	0.00229	CbGeAlD
Sorafenib—CYP3A4—renal system—kidney cancer	5.48e-05	0.00193	CbGeAlD
Sorafenib—CYP2D6—renal system—kidney cancer	5.39e-05	0.0019	CbGeAlD
Sorafenib—CYP3A4—kidney—kidney cancer	5.3e-05	0.00186	CbGeAlD
Sorafenib—Vismodegib—ABCB1—kidney cancer	5.24e-05	0.0254	CrCbGaD
Sorafenib—CYP2D6—kidney—kidney cancer	5.21e-05	0.00183	CbGeAlD
Sorafenib—ABCB1—nephron tubule—kidney cancer	4.27e-05	0.0015	CbGeAlD
Sorafenib—ABCB1—renal system—kidney cancer	3.88e-05	0.00136	CbGeAlD
Sorafenib—ABCB1—kidney—kidney cancer	3.75e-05	0.00132	CbGeAlD
Sorafenib—ABCB1—cortex of kidney—kidney cancer	3.65e-05	0.00128	CbGeAlD
Sorafenib—ABCB1—gonad—kidney cancer	3.48e-05	0.00122	CbGeAlD
Sorafenib—Gastrointestinal pain—Dactinomycin—kidney cancer	2.03e-05	0.000291	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Vincristine—kidney cancer	2.02e-05	0.000289	CcSEcCtD
Sorafenib—Urinary tract disorder—Capecitabine—kidney cancer	2.01e-05	0.000288	CcSEcCtD
Sorafenib—Dermatitis exfoliative—Doxorubicin—kidney cancer	2.01e-05	0.000288	CcSEcCtD
Sorafenib—Anorexia—Gemcitabine—kidney cancer	2.01e-05	0.000287	CcSEcCtD
Sorafenib—Vomiting—Vinblastine—kidney cancer	2e-05	0.000287	CcSEcCtD
Sorafenib—Dizziness—Erlotinib—kidney cancer	2e-05	0.000287	CcSEcCtD
Sorafenib—Connective tissue disorder—Capecitabine—kidney cancer	2e-05	0.000286	CcSEcCtD
Sorafenib—Vomiting—Everolimus—kidney cancer	2e-05	0.000286	CcSEcCtD
Sorafenib—Anaemia—Paclitaxel—kidney cancer	2e-05	0.000286	CcSEcCtD
Sorafenib—Urethral disorder—Capecitabine—kidney cancer	2e-05	0.000286	CcSEcCtD
Sorafenib—Rash—Everolimus—kidney cancer	1.98e-05	0.000284	CcSEcCtD
Sorafenib—Dermatitis—Everolimus—kidney cancer	1.98e-05	0.000283	CcSEcCtD
Sorafenib—Headache—Vinblastine—kidney cancer	1.97e-05	0.000283	CcSEcCtD
Sorafenib—Angioedema—Paclitaxel—kidney cancer	1.97e-05	0.000283	CcSEcCtD
Sorafenib—Headache—Everolimus—kidney cancer	1.97e-05	0.000282	CcSEcCtD
Sorafenib—Abdominal pain—Dactinomycin—kidney cancer	1.96e-05	0.000281	CcSEcCtD
Sorafenib—Body temperature increased—Dactinomycin—kidney cancer	1.96e-05	0.000281	CcSEcCtD
Sorafenib—Cardiac failure—Doxorubicin—kidney cancer	1.94e-05	0.000278	CcSEcCtD
Sorafenib—Syncope—Paclitaxel—kidney cancer	1.94e-05	0.000277	CcSEcCtD
Sorafenib—Leukopenia—Paclitaxel—kidney cancer	1.93e-05	0.000277	CcSEcCtD
Sorafenib—Hypersensitivity—Sunitinib—kidney cancer	1.93e-05	0.000277	CcSEcCtD
Sorafenib—Decreased appetite—Vincristine—kidney cancer	1.93e-05	0.000276	CcSEcCtD
Sorafenib—Vomiting—Erlotinib—kidney cancer	1.93e-05	0.000276	CcSEcCtD
Sorafenib—Erythema multiforme—Capecitabine—kidney cancer	1.92e-05	0.000276	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Gemcitabine—kidney cancer	1.92e-05	0.000275	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Vincristine—kidney cancer	1.92e-05	0.000274	CcSEcCtD
Sorafenib—Fatigue—Vincristine—kidney cancer	1.91e-05	0.000274	CcSEcCtD
Sorafenib—Rash—Erlotinib—kidney cancer	1.91e-05	0.000274	CcSEcCtD
Sorafenib—Dermatitis—Erlotinib—kidney cancer	1.91e-05	0.000273	CcSEcCtD
Sorafenib—Hyponatraemia—Doxorubicin—kidney cancer	1.9e-05	0.000273	CcSEcCtD
Sorafenib—Headache—Erlotinib—kidney cancer	1.9e-05	0.000272	CcSEcCtD
Sorafenib—Tinnitus—Capecitabine—kidney cancer	1.9e-05	0.000272	CcSEcCtD
Sorafenib—Loss of consciousness—Paclitaxel—kidney cancer	1.9e-05	0.000272	CcSEcCtD
Sorafenib—Pain—Vincristine—kidney cancer	1.9e-05	0.000272	CcSEcCtD
Sorafenib—Constipation—Vincristine—kidney cancer	1.9e-05	0.000272	CcSEcCtD
Sorafenib—Pain in extremity—Doxorubicin—kidney cancer	1.9e-05	0.000272	CcSEcCtD
Sorafenib—Flushing—Capecitabine—kidney cancer	1.89e-05	0.000271	CcSEcCtD
Sorafenib—Cardiac disorder—Capecitabine—kidney cancer	1.89e-05	0.000271	CcSEcCtD
Sorafenib—Cough—Paclitaxel—kidney cancer	1.88e-05	0.00027	CcSEcCtD
Sorafenib—Asthenia—Sunitinib—kidney cancer	1.88e-05	0.000269	CcSEcCtD
Sorafenib—Dyspnoea—Gemcitabine—kidney cancer	1.88e-05	0.000269	CcSEcCtD
Sorafenib—Nausea—Vinblastine—kidney cancer	1.87e-05	0.000268	CcSEcCtD
Sorafenib—Nausea—Everolimus—kidney cancer	1.87e-05	0.000267	CcSEcCtD
Sorafenib—Hypertension—Paclitaxel—kidney cancer	1.86e-05	0.000267	CcSEcCtD
Sorafenib—Pruritus—Sunitinib—kidney cancer	1.86e-05	0.000266	CcSEcCtD
Sorafenib—Angiopathy—Capecitabine—kidney cancer	1.85e-05	0.000264	CcSEcCtD
Sorafenib—Immune system disorder—Capecitabine—kidney cancer	1.84e-05	0.000263	CcSEcCtD
Sorafenib—Arthralgia—Paclitaxel—kidney cancer	1.84e-05	0.000263	CcSEcCtD
Sorafenib—Myalgia—Paclitaxel—kidney cancer	1.84e-05	0.000263	CcSEcCtD
Sorafenib—Mediastinal disorder—Capecitabine—kidney cancer	1.83e-05	0.000263	CcSEcCtD
Sorafenib—Decreased appetite—Gemcitabine—kidney cancer	1.83e-05	0.000262	CcSEcCtD
Sorafenib—Hypersensitivity—Dactinomycin—kidney cancer	1.83e-05	0.000262	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	1.83e-05	0.000261	CcSEcCtD
Sorafenib—Arrhythmia—Capecitabine—kidney cancer	1.82e-05	0.00026	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Gemcitabine—kidney cancer	1.82e-05	0.00026	CcSEcCtD
Sorafenib—Fatigue—Gemcitabine—kidney cancer	1.81e-05	0.00026	CcSEcCtD
Sorafenib—Gastrointestinal pain—Vincristine—kidney cancer	1.81e-05	0.00026	CcSEcCtD
Sorafenib—Pain—Gemcitabine—kidney cancer	1.8e-05	0.000258	CcSEcCtD
Sorafenib—Constipation—Gemcitabine—kidney cancer	1.8e-05	0.000258	CcSEcCtD
Sorafenib—Nausea—Erlotinib—kidney cancer	1.8e-05	0.000258	CcSEcCtD
Sorafenib—Alopecia—Capecitabine—kidney cancer	1.8e-05	0.000258	CcSEcCtD
Sorafenib—Dry mouth—Paclitaxel—kidney cancer	1.8e-05	0.000257	CcSEcCtD
Sorafenib—Mood swings—Doxorubicin—kidney cancer	1.8e-05	0.000257	CcSEcCtD
Sorafenib—Diarrhoea—Sunitinib—kidney cancer	1.79e-05	0.000257	CcSEcCtD
Sorafenib—Mental disorder—Capecitabine—kidney cancer	1.78e-05	0.000255	CcSEcCtD
Sorafenib—Asthenia—Dactinomycin—kidney cancer	1.78e-05	0.000255	CcSEcCtD
Sorafenib—Erythema—Capecitabine—kidney cancer	1.77e-05	0.000254	CcSEcCtD
Sorafenib—Malnutrition—Capecitabine—kidney cancer	1.77e-05	0.000254	CcSEcCtD
Sorafenib—Dehydration—Doxorubicin—kidney cancer	1.76e-05	0.000253	CcSEcCtD
Sorafenib—Anaphylactic shock—Paclitaxel—kidney cancer	1.76e-05	0.000252	CcSEcCtD
Sorafenib—Abdominal pain—Vincristine—kidney cancer	1.75e-05	0.000251	CcSEcCtD
Sorafenib—Body temperature increased—Vincristine—kidney cancer	1.75e-05	0.000251	CcSEcCtD
Sorafenib—Infection—Paclitaxel—kidney cancer	1.75e-05	0.000251	CcSEcCtD
Sorafenib—Dry skin—Doxorubicin—kidney cancer	1.74e-05	0.000249	CcSEcCtD
Sorafenib—Dysgeusia—Capecitabine—kidney cancer	1.74e-05	0.000248	CcSEcCtD
Sorafenib—Dizziness—Sunitinib—kidney cancer	1.73e-05	0.000248	CcSEcCtD
Sorafenib—Shock—Paclitaxel—kidney cancer	1.73e-05	0.000248	CcSEcCtD
Sorafenib—Abdominal pain upper—Doxorubicin—kidney cancer	1.73e-05	0.000248	CcSEcCtD
Sorafenib—Nervous system disorder—Paclitaxel—kidney cancer	1.73e-05	0.000247	CcSEcCtD
Sorafenib—Hypokalaemia—Doxorubicin—kidney cancer	1.73e-05	0.000247	CcSEcCtD
Sorafenib—Thrombocytopenia—Paclitaxel—kidney cancer	1.73e-05	0.000247	CcSEcCtD
Sorafenib—Breast disorder—Doxorubicin—kidney cancer	1.71e-05	0.000245	CcSEcCtD
Sorafenib—Skin disorder—Paclitaxel—kidney cancer	1.71e-05	0.000245	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	1.71e-05	0.000245	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	1.71e-05	0.000245	CcSEcCtD
Sorafenib—Muscle spasms—Capecitabine—kidney cancer	1.7e-05	0.000244	CcSEcCtD
Sorafenib—Diarrhoea—Dactinomycin—kidney cancer	1.7e-05	0.000243	CcSEcCtD
Sorafenib—Nasopharyngitis—Doxorubicin—kidney cancer	1.7e-05	0.000243	CcSEcCtD
Sorafenib—Anorexia—Paclitaxel—kidney cancer	1.68e-05	0.000241	CcSEcCtD
Sorafenib—Gastritis—Doxorubicin—kidney cancer	1.68e-05	0.00024	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Doxorubicin—kidney cancer	1.67e-05	0.00024	CcSEcCtD
Sorafenib—Vomiting—Sunitinib—kidney cancer	1.67e-05	0.000239	CcSEcCtD
Sorafenib—Body temperature increased—Gemcitabine—kidney cancer	1.66e-05	0.000238	CcSEcCtD
Sorafenib—Rash—Sunitinib—kidney cancer	1.65e-05	0.000237	CcSEcCtD
Sorafenib—Dermatitis—Sunitinib—kidney cancer	1.65e-05	0.000237	CcSEcCtD
Sorafenib—Headache—Sunitinib—kidney cancer	1.64e-05	0.000235	CcSEcCtD
Sorafenib—Dysphagia—Doxorubicin—kidney cancer	1.64e-05	0.000235	CcSEcCtD
Sorafenib—Anaemia—Capecitabine—kidney cancer	1.64e-05	0.000235	CcSEcCtD
Sorafenib—Hypersensitivity—Vincristine—kidney cancer	1.63e-05	0.000234	CcSEcCtD
Sorafenib—Pancreatitis—Doxorubicin—kidney cancer	1.61e-05	0.00023	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Paclitaxel—kidney cancer	1.61e-05	0.00023	CcSEcCtD
Sorafenib—Asthenia—Vincristine—kidney cancer	1.59e-05	0.000228	CcSEcCtD
Sorafenib—Syncope—Capecitabine—kidney cancer	1.59e-05	0.000228	CcSEcCtD
Sorafenib—Leukopenia—Capecitabine—kidney cancer	1.59e-05	0.000227	CcSEcCtD
Sorafenib—Vomiting—Dactinomycin—kidney cancer	1.58e-05	0.000226	CcSEcCtD
Sorafenib—Dyspnoea—Paclitaxel—kidney cancer	1.57e-05	0.000225	CcSEcCtD
Sorafenib—Rash—Dactinomycin—kidney cancer	1.57e-05	0.000224	CcSEcCtD
Sorafenib—Nausea—Sunitinib—kidney cancer	1.56e-05	0.000223	CcSEcCtD
Sorafenib—Loss of consciousness—Capecitabine—kidney cancer	1.56e-05	0.000223	CcSEcCtD
Sorafenib—Dyspepsia—Paclitaxel—kidney cancer	1.55e-05	0.000222	CcSEcCtD
Sorafenib—Cough—Capecitabine—kidney cancer	1.55e-05	0.000221	CcSEcCtD
Sorafenib—Neutropenia—Doxorubicin—kidney cancer	1.53e-05	0.000219	CcSEcCtD
Sorafenib—Decreased appetite—Paclitaxel—kidney cancer	1.53e-05	0.000219	CcSEcCtD
Sorafenib—Hypertension—Capecitabine—kidney cancer	1.53e-05	0.000219	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Paclitaxel—kidney cancer	1.52e-05	0.000218	CcSEcCtD
Sorafenib—Fatigue—Paclitaxel—kidney cancer	1.52e-05	0.000218	CcSEcCtD
Sorafenib—Diarrhoea—Vincristine—kidney cancer	1.52e-05	0.000217	CcSEcCtD
Sorafenib—Asthenia—Gemcitabine—kidney cancer	1.51e-05	0.000216	CcSEcCtD
Sorafenib—Arthralgia—Capecitabine—kidney cancer	1.51e-05	0.000216	CcSEcCtD
Sorafenib—Myalgia—Capecitabine—kidney cancer	1.51e-05	0.000216	CcSEcCtD
Sorafenib—Pain—Paclitaxel—kidney cancer	1.51e-05	0.000216	CcSEcCtD
Sorafenib—Constipation—Paclitaxel—kidney cancer	1.51e-05	0.000216	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	1.5e-05	0.000215	CcSEcCtD
Sorafenib—Pruritus—Gemcitabine—kidney cancer	1.49e-05	0.000213	CcSEcCtD
Sorafenib—Weight decreased—Doxorubicin—kidney cancer	1.48e-05	0.000212	CcSEcCtD
Sorafenib—Dry mouth—Capecitabine—kidney cancer	1.48e-05	0.000211	CcSEcCtD
Sorafenib—Nausea—Dactinomycin—kidney cancer	1.47e-05	0.000211	CcSEcCtD
Sorafenib—Pneumonia—Doxorubicin—kidney cancer	1.47e-05	0.000211	CcSEcCtD
Sorafenib—Dizziness—Vincristine—kidney cancer	1.47e-05	0.00021	CcSEcCtD
Sorafenib—Infestation—Doxorubicin—kidney cancer	1.46e-05	0.000209	CcSEcCtD
Sorafenib—Infestation NOS—Doxorubicin—kidney cancer	1.46e-05	0.000209	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	1.45e-05	0.000207	CcSEcCtD
Sorafenib—Gastrointestinal pain—Paclitaxel—kidney cancer	1.44e-05	0.000206	CcSEcCtD
Sorafenib—Diarrhoea—Gemcitabine—kidney cancer	1.44e-05	0.000206	CcSEcCtD
Sorafenib—Renal failure—Doxorubicin—kidney cancer	1.44e-05	0.000206	CcSEcCtD
Sorafenib—Infection—Capecitabine—kidney cancer	1.44e-05	0.000206	CcSEcCtD
Sorafenib—Neuropathy peripheral—Doxorubicin—kidney cancer	1.43e-05	0.000205	CcSEcCtD
Sorafenib—Stomatitis—Doxorubicin—kidney cancer	1.42e-05	0.000204	CcSEcCtD
Sorafenib—Jaundice—Doxorubicin—kidney cancer	1.42e-05	0.000204	CcSEcCtD
Sorafenib—Shock—Capecitabine—kidney cancer	1.42e-05	0.000204	CcSEcCtD
Sorafenib—Nervous system disorder—Capecitabine—kidney cancer	1.42e-05	0.000203	CcSEcCtD
Sorafenib—Thrombocytopenia—Capecitabine—kidney cancer	1.42e-05	0.000203	CcSEcCtD
Sorafenib—Vomiting—Vincristine—kidney cancer	1.41e-05	0.000202	CcSEcCtD
Sorafenib—Skin disorder—Capecitabine—kidney cancer	1.4e-05	0.000201	CcSEcCtD
Sorafenib—Urticaria—Paclitaxel—kidney cancer	1.4e-05	0.0002	CcSEcCtD
Sorafenib—Rash—Vincristine—kidney cancer	1.4e-05	0.0002	CcSEcCtD
Sorafenib—Dermatitis—Vincristine—kidney cancer	1.4e-05	0.0002	CcSEcCtD
Sorafenib—Abdominal pain—Paclitaxel—kidney cancer	1.39e-05	0.000199	CcSEcCtD
Sorafenib—Body temperature increased—Paclitaxel—kidney cancer	1.39e-05	0.000199	CcSEcCtD
Sorafenib—Headache—Vincristine—kidney cancer	1.39e-05	0.000199	CcSEcCtD
Sorafenib—Hepatobiliary disease—Doxorubicin—kidney cancer	1.38e-05	0.000198	CcSEcCtD
Sorafenib—Epistaxis—Doxorubicin—kidney cancer	1.38e-05	0.000197	CcSEcCtD
Sorafenib—Anorexia—Capecitabine—kidney cancer	1.38e-05	0.000197	CcSEcCtD
Sorafenib—Vomiting—Gemcitabine—kidney cancer	1.34e-05	0.000192	CcSEcCtD
Sorafenib—Rash—Gemcitabine—kidney cancer	1.33e-05	0.00019	CcSEcCtD
Sorafenib—Dermatitis—Gemcitabine—kidney cancer	1.33e-05	0.00019	CcSEcCtD
Sorafenib—Haemoglobin—Doxorubicin—kidney cancer	1.32e-05	0.000189	CcSEcCtD
Sorafenib—Headache—Gemcitabine—kidney cancer	1.32e-05	0.000189	CcSEcCtD
Sorafenib—Nausea—Vincristine—kidney cancer	1.32e-05	0.000189	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Capecitabine—kidney cancer	1.32e-05	0.000189	CcSEcCtD
Sorafenib—Haemorrhage—Doxorubicin—kidney cancer	1.31e-05	0.000188	CcSEcCtD
Sorafenib—Hypersensitivity—Paclitaxel—kidney cancer	1.3e-05	0.000186	CcSEcCtD
Sorafenib—Urinary tract disorder—Doxorubicin—kidney cancer	1.3e-05	0.000186	CcSEcCtD
Sorafenib—Connective tissue disorder—Doxorubicin—kidney cancer	1.29e-05	0.000185	CcSEcCtD
Sorafenib—Dyspnoea—Capecitabine—kidney cancer	1.29e-05	0.000185	CcSEcCtD
Sorafenib—Urethral disorder—Doxorubicin—kidney cancer	1.29e-05	0.000184	CcSEcCtD
Sorafenib—Dyspepsia—Capecitabine—kidney cancer	1.27e-05	0.000182	CcSEcCtD
Sorafenib—Asthenia—Paclitaxel—kidney cancer	1.26e-05	0.000181	CcSEcCtD
Sorafenib—Decreased appetite—Capecitabine—kidney cancer	1.26e-05	0.00018	CcSEcCtD
Sorafenib—Nausea—Gemcitabine—kidney cancer	1.25e-05	0.000179	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Capecitabine—kidney cancer	1.25e-05	0.000179	CcSEcCtD
Sorafenib—Fatigue—Capecitabine—kidney cancer	1.25e-05	0.000179	CcSEcCtD
Sorafenib—Pruritus—Paclitaxel—kidney cancer	1.25e-05	0.000179	CcSEcCtD
Sorafenib—Erythema multiforme—Doxorubicin—kidney cancer	1.24e-05	0.000178	CcSEcCtD
Sorafenib—Pain—Capecitabine—kidney cancer	1.24e-05	0.000177	CcSEcCtD
Sorafenib—Constipation—Capecitabine—kidney cancer	1.24e-05	0.000177	CcSEcCtD
Sorafenib—Tinnitus—Doxorubicin—kidney cancer	1.22e-05	0.000175	CcSEcCtD
Sorafenib—Flushing—Doxorubicin—kidney cancer	1.22e-05	0.000174	CcSEcCtD
Sorafenib—Cardiac disorder—Doxorubicin—kidney cancer	1.22e-05	0.000174	CcSEcCtD
Sorafenib—Diarrhoea—Paclitaxel—kidney cancer	1.21e-05	0.000173	CcSEcCtD
Sorafenib—Angiopathy—Doxorubicin—kidney cancer	1.19e-05	0.00017	CcSEcCtD
Sorafenib—Immune system disorder—Doxorubicin—kidney cancer	1.19e-05	0.00017	CcSEcCtD
Sorafenib—Gastrointestinal pain—Capecitabine—kidney cancer	1.18e-05	0.000169	CcSEcCtD
Sorafenib—Mediastinal disorder—Doxorubicin—kidney cancer	1.18e-05	0.000169	CcSEcCtD
Sorafenib—Arrhythmia—Doxorubicin—kidney cancer	1.17e-05	0.000168	CcSEcCtD
Sorafenib—Dizziness—Paclitaxel—kidney cancer	1.17e-05	0.000167	CcSEcCtD
Sorafenib—Alopecia—Doxorubicin—kidney cancer	1.16e-05	0.000166	CcSEcCtD
Sorafenib—Mental disorder—Doxorubicin—kidney cancer	1.15e-05	0.000165	CcSEcCtD
Sorafenib—Urticaria—Capecitabine—kidney cancer	1.15e-05	0.000165	CcSEcCtD
Sorafenib—Body temperature increased—Capecitabine—kidney cancer	1.14e-05	0.000164	CcSEcCtD
Sorafenib—Abdominal pain—Capecitabine—kidney cancer	1.14e-05	0.000164	CcSEcCtD
Sorafenib—Malnutrition—Doxorubicin—kidney cancer	1.14e-05	0.000164	CcSEcCtD
Sorafenib—Erythema—Doxorubicin—kidney cancer	1.14e-05	0.000164	CcSEcCtD
Sorafenib—Vomiting—Paclitaxel—kidney cancer	1.12e-05	0.00016	CcSEcCtD
Sorafenib—Dysgeusia—Doxorubicin—kidney cancer	1.12e-05	0.00016	CcSEcCtD
Sorafenib—Rash—Paclitaxel—kidney cancer	1.11e-05	0.000159	CcSEcCtD
Sorafenib—Dermatitis—Paclitaxel—kidney cancer	1.11e-05	0.000159	CcSEcCtD
Sorafenib—Headache—Paclitaxel—kidney cancer	1.1e-05	0.000158	CcSEcCtD
Sorafenib—Muscle spasms—Doxorubicin—kidney cancer	1.1e-05	0.000157	CcSEcCtD
Sorafenib—Hypersensitivity—Capecitabine—kidney cancer	1.07e-05	0.000153	CcSEcCtD
Sorafenib—Anaemia—Doxorubicin—kidney cancer	1.06e-05	0.000151	CcSEcCtD
Sorafenib—Nausea—Paclitaxel—kidney cancer	1.05e-05	0.00015	CcSEcCtD
Sorafenib—Asthenia—Capecitabine—kidney cancer	1.04e-05	0.000149	CcSEcCtD
Sorafenib—Syncope—Doxorubicin—kidney cancer	1.02e-05	0.000147	CcSEcCtD
Sorafenib—Pruritus—Capecitabine—kidney cancer	1.02e-05	0.000147	CcSEcCtD
Sorafenib—Leukopenia—Doxorubicin—kidney cancer	1.02e-05	0.000146	CcSEcCtD
Sorafenib—Loss of consciousness—Doxorubicin—kidney cancer	1e-05	0.000144	CcSEcCtD
Sorafenib—Cough—Doxorubicin—kidney cancer	9.97e-06	0.000143	CcSEcCtD
Sorafenib—Diarrhoea—Capecitabine—kidney cancer	9.89e-06	0.000142	CcSEcCtD
Sorafenib—Hypertension—Doxorubicin—kidney cancer	9.86e-06	0.000141	CcSEcCtD
Sorafenib—Arthralgia—Doxorubicin—kidney cancer	9.72e-06	0.000139	CcSEcCtD
Sorafenib—Myalgia—Doxorubicin—kidney cancer	9.72e-06	0.000139	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	9.66e-06	0.000138	CcSEcCtD
Sorafenib—Dizziness—Capecitabine—kidney cancer	9.56e-06	0.000137	CcSEcCtD
Sorafenib—Dry mouth—Doxorubicin—kidney cancer	9.51e-06	0.000136	CcSEcCtD
Sorafenib—Anaphylactic shock—Doxorubicin—kidney cancer	9.32e-06	0.000133	CcSEcCtD
Sorafenib—Infection—Doxorubicin—kidney cancer	9.26e-06	0.000133	CcSEcCtD
Sorafenib—Vomiting—Capecitabine—kidney cancer	9.19e-06	0.000132	CcSEcCtD
Sorafenib—Shock—Doxorubicin—kidney cancer	9.17e-06	0.000131	CcSEcCtD
Sorafenib—Nervous system disorder—Doxorubicin—kidney cancer	9.14e-06	0.000131	CcSEcCtD
Sorafenib—Thrombocytopenia—Doxorubicin—kidney cancer	9.13e-06	0.000131	CcSEcCtD
Sorafenib—Rash—Capecitabine—kidney cancer	9.12e-06	0.000131	CcSEcCtD
Sorafenib—Dermatitis—Capecitabine—kidney cancer	9.11e-06	0.00013	CcSEcCtD
Sorafenib—Headache—Capecitabine—kidney cancer	9.06e-06	0.00013	CcSEcCtD
Sorafenib—Skin disorder—Doxorubicin—kidney cancer	9.05e-06	0.00013	CcSEcCtD
Sorafenib—Anorexia—Doxorubicin—kidney cancer	8.89e-06	0.000127	CcSEcCtD
Sorafenib—Nausea—Capecitabine—kidney cancer	8.59e-06	0.000123	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Doxorubicin—kidney cancer	8.49e-06	0.000122	CcSEcCtD
Sorafenib—Dyspnoea—Doxorubicin—kidney cancer	8.31e-06	0.000119	CcSEcCtD
Sorafenib—Dyspepsia—Doxorubicin—kidney cancer	8.21e-06	0.000117	CcSEcCtD
Sorafenib—Decreased appetite—Doxorubicin—kidney cancer	8.1e-06	0.000116	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Doxorubicin—kidney cancer	8.05e-06	0.000115	CcSEcCtD
Sorafenib—Fatigue—Doxorubicin—kidney cancer	8.04e-06	0.000115	CcSEcCtD
Sorafenib—Pain—Doxorubicin—kidney cancer	7.97e-06	0.000114	CcSEcCtD
Sorafenib—Constipation—Doxorubicin—kidney cancer	7.97e-06	0.000114	CcSEcCtD
Sorafenib—Gastrointestinal pain—Doxorubicin—kidney cancer	7.62e-06	0.000109	CcSEcCtD
Sorafenib—Urticaria—Doxorubicin—kidney cancer	7.4e-06	0.000106	CcSEcCtD
Sorafenib—Body temperature increased—Doxorubicin—kidney cancer	7.37e-06	0.000106	CcSEcCtD
Sorafenib—Abdominal pain—Doxorubicin—kidney cancer	7.37e-06	0.000106	CcSEcCtD
Sorafenib—Hypersensitivity—Doxorubicin—kidney cancer	6.87e-06	9.83e-05	CcSEcCtD
Sorafenib—Asthenia—Doxorubicin—kidney cancer	6.69e-06	9.58e-05	CcSEcCtD
Sorafenib—Pruritus—Doxorubicin—kidney cancer	6.59e-06	9.44e-05	CcSEcCtD
Sorafenib—Diarrhoea—Doxorubicin—kidney cancer	6.38e-06	9.13e-05	CcSEcCtD
Sorafenib—Dizziness—Doxorubicin—kidney cancer	6.16e-06	8.83e-05	CcSEcCtD
Sorafenib—Vomiting—Doxorubicin—kidney cancer	5.93e-06	8.49e-05	CcSEcCtD
Sorafenib—Rash—Doxorubicin—kidney cancer	5.88e-06	8.42e-05	CcSEcCtD
Sorafenib—Dermatitis—Doxorubicin—kidney cancer	5.87e-06	8.41e-05	CcSEcCtD
Sorafenib—Headache—Doxorubicin—kidney cancer	5.84e-06	8.36e-05	CcSEcCtD
Sorafenib—Nausea—Doxorubicin—kidney cancer	5.54e-06	7.93e-05	CcSEcCtD
Sorafenib—MAP2K5—Signaling Pathways—KRAS—kidney cancer	4.99e-07	9.25e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—KRAS—kidney cancer	4.98e-07	9.22e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MYC—kidney cancer	4.97e-07	9.21e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—RAF1—kidney cancer	4.97e-07	9.2e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL2—kidney cancer	4.96e-07	9.18e-06	CbGpPWpGaD
Sorafenib—KIT—Disease—PIK3CA—kidney cancer	4.95e-07	9.17e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—RELA—kidney cancer	4.94e-07	9.16e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL2—kidney cancer	4.94e-07	9.16e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—MAPK3—kidney cancer	4.94e-07	9.14e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PSMD7—kidney cancer	4.93e-07	9.14e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—VEGFA—kidney cancer	4.92e-07	9.12e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GSTM1—kidney cancer	4.92e-07	9.11e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—ERBB2—kidney cancer	4.91e-07	9.1e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PTEN—kidney cancer	4.91e-07	9.1e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PTEN—kidney cancer	4.91e-07	9.1e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CRABP1—kidney cancer	4.89e-07	9.05e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—VEGFA—kidney cancer	4.88e-07	9.03e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KIT—kidney cancer	4.87e-07	9.02e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—APC—kidney cancer	4.87e-07	9.02e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—KRAS—kidney cancer	4.87e-07	9.01e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MAPK1—kidney cancer	4.86e-07	9.01e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—KRAS—kidney cancer	4.85e-07	8.99e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MTOR—kidney cancer	4.85e-07	8.98e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.85e-07	8.98e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCND1—kidney cancer	4.83e-07	8.95e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—JUN—kidney cancer	4.82e-07	8.93e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCND1—kidney cancer	4.82e-07	8.93e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—JUN—kidney cancer	4.81e-07	8.91e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CTNNB1—kidney cancer	4.78e-07	8.86e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GSTP1—kidney cancer	4.78e-07	8.85e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—PIK3CA—kidney cancer	4.77e-07	8.84e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CTNNB1—kidney cancer	4.77e-07	8.84e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—RAF1—kidney cancer	4.74e-07	8.77e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—RELA—kidney cancer	4.72e-07	8.74e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—PIK3CA—kidney cancer	4.7e-07	8.7e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—MAPK1—kidney cancer	4.7e-07	8.7e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—ERBB2—kidney cancer	4.69e-07	8.68e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—PIK3CA—kidney cancer	4.69e-07	8.68e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—BCHE—kidney cancer	4.68e-07	8.66e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PTEN—kidney cancer	4.66e-07	8.64e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—MAPK3—kidney cancer	4.66e-07	8.64e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GSTP1—kidney cancer	4.66e-07	8.64e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CYP1A1—kidney cancer	4.66e-07	8.64e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MAPK3—kidney cancer	4.66e-07	8.62e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PTEN—kidney cancer	4.65e-07	8.62e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—POMC—kidney cancer	4.63e-07	8.59e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MTOR—kidney cancer	4.62e-07	8.57e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SLC5A5—kidney cancer	4.62e-07	8.56e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MAPK3—kidney cancer	4.61e-07	8.54e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—KRAS—kidney cancer	4.59e-07	8.51e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTEN—kidney cancer	4.59e-07	8.5e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTEN—kidney cancer	4.59e-07	8.5e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—PIK3CA—kidney cancer	4.59e-07	8.5e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—BRAF—kidney cancer	4.58e-07	8.48e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—PIK3CA—kidney cancer	4.57e-07	8.47e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—MAPK3—kidney cancer	4.56e-07	8.44e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CDKN1B—kidney cancer	4.55e-07	8.43e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ITPR2—kidney cancer	4.54e-07	8.42e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MYC—kidney cancer	4.53e-07	8.39e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ABCB1—kidney cancer	4.52e-07	8.38e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MYC—kidney cancer	4.49e-07	8.31e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—PIK3CA—kidney cancer	4.47e-07	8.28e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—kidney cancer	4.47e-07	8.27e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SLC2A1—kidney cancer	4.46e-07	8.27e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—PIK3CA—kidney cancer	4.46e-07	8.26e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL2—kidney cancer	4.45e-07	8.25e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VEGFA—kidney cancer	4.44e-07	8.22e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VEGFA—kidney cancer	4.44e-07	8.22e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—kidney cancer	4.44e-07	8.22e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—MAPK1—kidney cancer	4.44e-07	8.22e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KRAS—kidney cancer	4.44e-07	8.22e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—MYC—kidney cancer	4.43e-07	8.21e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MAPK1—kidney cancer	4.43e-07	8.21e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—kidney cancer	4.43e-07	8.2e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.42e-07	8.18e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—RELA—kidney cancer	4.41e-07	8.16e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTP1—kidney cancer	4.39e-07	8.14e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GSTM1—kidney cancer	4.39e-07	8.13e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MAPK1—kidney cancer	4.39e-07	8.13e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—ERBB2—kidney cancer	4.38e-07	8.11e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTP1—kidney cancer	4.36e-07	8.07e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCND1—kidney cancer	4.34e-07	8.04e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CDKN1B—kidney cancer	4.34e-07	8.04e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—MAPK1—kidney cancer	4.34e-07	8.03e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—JUN—kidney cancer	4.33e-07	8.02e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.33e-07	8.02e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—kidney cancer	4.32e-07	8.01e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MTOR—kidney cancer	4.32e-07	8.01e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CTNNB1—kidney cancer	4.3e-07	7.96e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GSTM1—kidney cancer	4.28e-07	7.94e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL2—kidney cancer	4.25e-07	7.87e-06	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—PIK3CA—kidney cancer	4.24e-07	7.85e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PIK3CA—kidney cancer	4.22e-07	7.82e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—kidney cancer	4.21e-07	7.8e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—kidney cancer	4.2e-07	7.78e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MAPK3—kidney cancer	4.2e-07	7.78e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MAPK3—kidney cancer	4.2e-07	7.78e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—KRAS—kidney cancer	4.19e-07	7.76e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PTEN—kidney cancer	4.19e-07	7.76e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KRAS—kidney cancer	4.18e-07	7.75e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP1A1—kidney cancer	4.16e-07	7.71e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ABCB1—kidney cancer	4.16e-07	7.7e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KRAS—kidney cancer	4.15e-07	7.68e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ACHE—kidney cancer	4.14e-07	7.68e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTT1—kidney cancer	4.14e-07	7.68e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCND1—kidney cancer	4.14e-07	7.67e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—JUN—kidney cancer	4.13e-07	7.65e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ABCB1—kidney cancer	4.12e-07	7.64e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—POMC—kidney cancer	4.11e-07	7.6e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CTNNB1—kidney cancer	4.1e-07	7.59e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—KRAS—kidney cancer	4.1e-07	7.59e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MYC—kidney cancer	4.08e-07	7.56e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MYC—kidney cancer	4.08e-07	7.56e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PIK3CA—kidney cancer	4.08e-07	7.55e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP1A1—kidney cancer	4.06e-07	7.52e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1B—kidney cancer	4.06e-07	7.51e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTM1—kidney cancer	4.04e-07	7.48e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—POMC—kidney cancer	4.01e-07	7.43e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTM1—kidney cancer	4e-07	7.41e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PTEN—kidney cancer	4e-07	7.4e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MAPK1—kidney cancer	3.99e-07	7.4e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MAPK1—kidney cancer	3.99e-07	7.4e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK3—kidney cancer	3.98e-07	7.38e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK3—kidney cancer	3.97e-07	7.36e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—kidney cancer	3.97e-07	7.35e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SCARB1—kidney cancer	3.92e-07	7.27e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTEN—kidney cancer	3.9e-07	7.22e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS1—kidney cancer	3.88e-07	7.19e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—kidney cancer	3.88e-07	7.18e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCND1—kidney cancer	3.87e-07	7.17e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—kidney cancer	3.87e-07	7.16e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTEN—kidney cancer	3.86e-07	7.15e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—JUN—kidney cancer	3.86e-07	7.15e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—PIK3CA—kidney cancer	3.85e-07	7.13e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PIK3CA—kidney cancer	3.84e-07	7.12e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CTNNB1—kidney cancer	3.83e-07	7.1e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.83e-07	7.09e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP1A1—kidney cancer	3.83e-07	7.09e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—RAF1—kidney cancer	3.82e-07	7.08e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PIK3CA—kidney cancer	3.81e-07	7.05e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PSMD7—kidney cancer	3.81e-07	7.05e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—RELA—kidney cancer	3.8e-07	7.05e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP1A1—kidney cancer	3.79e-07	7.03e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK1—kidney cancer	3.79e-07	7.02e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—kidney cancer	3.78e-07	7.01e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK1—kidney cancer	3.78e-07	7e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ERBB2—kidney cancer	3.78e-07	7e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.78e-07	6.99e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—kidney cancer	3.77e-07	6.99e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—kidney cancer	3.77e-07	6.99e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—PIK3CA—kidney cancer	3.76e-07	6.97e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTEN—kidney cancer	3.73e-07	6.92e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MTOR—kidney cancer	3.73e-07	6.91e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTP1—kidney cancer	3.72e-07	6.89e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—kidney cancer	3.72e-07	6.89e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—kidney cancer	3.68e-07	6.82e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—BCHE—kidney cancer	3.61e-07	6.69e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—kidney cancer	3.61e-07	6.69e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—kidney cancer	3.58e-07	6.63e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK3—kidney cancer	3.58e-07	6.63e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—kidney cancer	3.57e-07	6.62e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC5A5—kidney cancer	3.57e-07	6.6e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCB1—kidney cancer	3.52e-07	6.53e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	3.5e-07	6.49e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—kidney cancer	3.48e-07	6.45e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—POMC—kidney cancer	3.48e-07	6.44e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PIK3CA—kidney cancer	3.47e-07	6.42e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PIK3CA—kidney cancer	3.47e-07	6.42e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC2A1—kidney cancer	3.44e-07	6.38e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—kidney cancer	3.43e-07	6.35e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTM1—kidney cancer	3.42e-07	6.34e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.42e-07	6.33e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK3—kidney cancer	3.41e-07	6.32e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK1—kidney cancer	3.41e-07	6.31e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—kidney cancer	3.37e-07	6.25e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—kidney cancer	3.35e-07	6.21e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—kidney cancer	3.35e-07	6.21e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—kidney cancer	3.34e-07	6.19e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—JUN—kidney cancer	3.33e-07	6.17e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—kidney cancer	3.32e-07	6.15e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	3.31e-07	6.13e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PIK3CA—kidney cancer	3.29e-07	6.09e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PIK3CA—kidney cancer	3.28e-07	6.08e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—kidney cancer	3.27e-07	6.07e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK1—kidney cancer	3.25e-07	6.02e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP1A1—kidney cancer	3.24e-07	6.01e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3CA—kidney cancer	3.24e-07	6e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3CA—kidney cancer	3.24e-07	6e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTEN—kidney cancer	3.22e-07	5.97e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—kidney cancer	3.22e-07	5.96e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—kidney cancer	3.2e-07	5.93e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK3—kidney cancer	3.19e-07	5.91e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—kidney cancer	3.18e-07	5.89e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—kidney cancer	3.17e-07	5.88e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.12e-07	5.77e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—kidney cancer	3.1e-07	5.75e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—POMC—kidney cancer	3.1e-07	5.75e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—kidney cancer	3.07e-07	5.68e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK1—kidney cancer	3.04e-07	5.62e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—POMC—kidney cancer	3.03e-07	5.61e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PIK3CA—kidney cancer	2.96e-07	5.48e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—kidney cancer	2.91e-07	5.39e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTP1—kidney cancer	2.87e-07	5.32e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—kidney cancer	2.87e-07	5.31e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—kidney cancer	2.86e-07	5.3e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTEN—kidney cancer	2.86e-07	5.29e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—POMC—kidney cancer	2.85e-07	5.29e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—POMC—kidney cancer	2.83e-07	5.24e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PIK3CA—kidney cancer	2.82e-07	5.22e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTEN—kidney cancer	2.79e-07	5.17e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—kidney cancer	2.77e-07	5.14e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK3—kidney cancer	2.75e-07	5.1e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3CA—kidney cancer	2.75e-07	5.09e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—kidney cancer	2.73e-07	5.05e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3CA—kidney cancer	2.72e-07	5.05e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCB1—kidney cancer	2.72e-07	5.04e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—kidney cancer	2.68e-07	4.96e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.66e-07	4.93e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTM1—kidney cancer	2.64e-07	4.89e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PIK3CA—kidney cancer	2.63e-07	4.88e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK1—kidney cancer	2.62e-07	4.86e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—kidney cancer	2.55e-07	4.72e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP1A1—kidney cancer	2.5e-07	4.63e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—kidney cancer	2.48e-07	4.59e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—kidney cancer	2.47e-07	4.58e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTEN—kidney cancer	2.42e-07	4.48e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—POMC—kidney cancer	2.42e-07	4.48e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—kidney cancer	2.42e-07	4.47e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—kidney cancer	2.28e-07	4.22e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	2.27e-07	4.21e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—kidney cancer	2.26e-07	4.18e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—kidney cancer	2.2e-07	4.08e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTEN—kidney cancer	2.16e-07	4e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTEN—kidney cancer	2.11e-07	3.9e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CA—kidney cancer	2.01e-07	3.73e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTEN—kidney cancer	1.98e-07	3.68e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CA—kidney cancer	1.97e-07	3.65e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTEN—kidney cancer	1.97e-07	3.64e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—kidney cancer	1.93e-07	3.57e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—POMC—kidney cancer	1.87e-07	3.46e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CA—kidney cancer	1.71e-07	3.16e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTEN—kidney cancer	1.68e-07	3.11e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CA—kidney cancer	1.52e-07	2.82e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—kidney cancer	1.49e-07	2.76e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CA—kidney cancer	1.49e-07	2.75e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.4e-07	2.59e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.39e-07	2.57e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTEN—kidney cancer	1.3e-07	2.4e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CA—kidney cancer	1.19e-07	2.2e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CA—kidney cancer	9.15e-08	1.7e-06	CbGpPWpGaD
